Related Experiment Videos
Differentiated dosage of microporous colestyramine and its double-blind comparison with a placebo in
T Di Perri1, M Franchi, M Bruno
1Department of Internal Medicine, University of Siena, Italy.
Abstract:
A double-blind trial of microporous colestyramine (MPC) at different dosages was undertaken on 18 hypercholesterolaemic patients (Fredrickson classification Type II A) in three groups. During the attack phase of four weeks, three dosage regimens of MPC were used, 9 g, 12 g and 18 g for six patients in each group. During the maintenance phase of eight weeks, the patients were divided into two groups of nine each, one group receiving MPC 9 g/day and the other a placebo. The attack phase demonstrated the efficacy of the MPC therapy at all three dosage levels with minimal side-effects and the maintenance phase showed significant adverse variations in the total and HDL-cholesterol levels and in the intraratio in the placebo group, and in the physician's and patients judgement of the efficacy of the MPC therapy compared with the placebo. It is considered that MPC provides an excellent alternative therapy for prolonged treatment of hypercholesterolaemia, where a specific diet therapy is unacceptable.
Insights
Microporous colestyramine (MPC) effectively treated hypercholesterolaemia in patients. MPC offers a viable alternative for long-term cholesterol management when diet therapy is not feasible.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypercholesterolaemia poses significant cardiovascular risks.
- Dietary interventions are primary but adherence can be challenging.
Purpose of the Study:
- To evaluate the efficacy and safety of microporous colestyramine (MPC) in treating hypercholesterolaemia.
- To compare MPC therapy against a placebo in a maintenance phase.
Main Methods:
- A double-blind trial involving 18 hypercholesterolaemic patients (Type II A).
- Four-week attack phase with MPC dosages of 9g, 12g, and 18g.
- Eight-week maintenance phase comparing MPC 9g/day to placebo.
Main Results:
- MPC demonstrated efficacy across all tested dosages during the attack phase with minimal side-effects.
- The placebo group showed adverse changes in total cholesterol, HDL-cholesterol, and cholesterol intraratio during maintenance.
- Physicians and patients reported better efficacy for MPC compared to placebo.
Conclusions:
- Microporous colestyramine (MPC) is an effective treatment for hypercholesterolaemia.
- MPC presents a valuable alternative for prolonged hypercholesterolaemia management, especially when diet is not tolerated.